Clinical Trial Update: A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED) [Phase 2, Phase 3]

View source ↗

Summary

This document notes an ongoing Phase 2b/Phase 3 trial evaluating linsitinib for Thyroid Eye Disease, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Orbitopathy
• Thyroid Eye Disease

Drugs mentioned

• Linsitinib (linsitinib)

Snippet

Sponsor: Sling Therapeutics, Inc. | Conditions: Thyroid Eye Disease, Graves Orbitopathy | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING